Free Trial

Cypress Advisory Group LLC Buys 1,395 Shares of Danaher Co. (NYSE:DHR)

Danaher logo with Medical background

Cypress Advisory Group LLC increased its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 87.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,995 shares of the conglomerate's stock after acquiring an additional 1,395 shares during the quarter. Cypress Advisory Group LLC's holdings in Danaher were worth $614,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of DHR. Adero Partners LLC grew its stake in shares of Danaher by 11.2% in the 1st quarter. Adero Partners LLC now owns 1,953 shares of the conglomerate's stock valued at $400,000 after buying an additional 197 shares during the period. Sowell Financial Services LLC acquired a new stake in Danaher in the first quarter valued at approximately $1,442,000. Mission Wealth Management LP increased its holdings in shares of Danaher by 0.7% during the first quarter. Mission Wealth Management LP now owns 13,096 shares of the conglomerate's stock valued at $2,685,000 after acquiring an additional 96 shares in the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH raised its position in shares of Danaher by 1.6% during the first quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 15,107 shares of the conglomerate's stock worth $3,097,000 after purchasing an additional 241 shares during the period. Finally, Brown Miller Wealth Management LLC grew its position in Danaher by 6.6% in the 1st quarter. Brown Miller Wealth Management LLC now owns 3,508 shares of the conglomerate's stock valued at $719,000 after purchasing an additional 218 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DHR has been the topic of several research reports. Guggenheim restated a "buy" rating and set a $250.00 price objective on shares of Danaher in a report on Wednesday, April 23rd. HSBC lowered their target price on shares of Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Wolfe Research decreased their price objective on Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a report on Monday, April 7th. Robert W. Baird lowered their price objective on Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. Finally, Stifel Nicolaus raised Danaher from a "hold" rating to a "buy" rating and set a $260.00 target price on the stock in a research report on Friday, March 14th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $248.17.

View Our Latest Analysis on DHR

Danaher Trading Down 2.2%

Shares of DHR stock opened at $200.51 on Monday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The firm has a market cap of $143.50 billion, a P/E ratio of 37.98, a PEG ratio of 2.66 and a beta of 0.77. The company has a 50 day moving average of $192.80 and a 200-day moving average of $210.81. Danaher Co. has a 12-month low of $171.00 and a 12-month high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Sell-side analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.64%. Danaher's dividend payout ratio is currently 24.85%.

Insiders Place Their Bets

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president now owns 15,179 shares of the company's stock, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Recommended Stories

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Oil Spikes Amid Rising Warfare: 3 Stocks to Watch Now
Palantir at All-Time Highs: Take Profits or Hold the Line?
3 Tech Stocks Insiders Are Buying: Speculative Plays for June

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines